Exactly, thanks for that Snoball, they rushed it to a big trial without any real evidence for clinical efficacy, (they used a surrogate endpoint, always a dangerous practice) and then bombed big time. PRR on the other hand, have established clinical efficacy first, before launching Phase II/III. This is a credit to management that they are careful with shareholders money.
abagovomab vs oregovomab - facts ..., page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.005(1.27%) |
Mkt cap ! $569.8M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $307.5K | 779.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 657300 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 299356 | 22 |
View Market Depth
| Last trade - 13.11pm 19/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |